<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6501">
  <stage>Registered</stage>
  <submitdate>18/05/2017</submitdate>
  <approvaldate>18/05/2017</approvaldate>
  <nctid>NCT03165864</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers</studytitle>
    <scientifictitle>A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 702843 Administered Subcutaneously to Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ISIS 702843-CS1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Thalassemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IONIS TMPRSS6-Lrx
Other interventions - Placebo

Experimental: IONIS TMPRSS6-Lrx - Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously

Placebo Comparator: Placebo - Saline .9%


Treatment: drugs: IONIS TMPRSS6-Lrx
Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously

Other interventions: Placebo
Saline .9%

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence and severity of adverse events that are related to treatment with IONIS TMPRSS6-Lrx - The safety and tolerability of single and multiple doses of IONIS TMPRSS6-Lrx will be assessed by determining the incidence, severity, and dose relationship of adverse events that are related to treatment with IONIS TMPRSS6-Lrx</outcome>
      <timepoint>Up to 148 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (maximum observed drug concentration or Cmax) - The plasma pharmacokinetics (maximum observed drug concentration or Cmax) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</outcome>
      <timepoint>Up to 148 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (time taken to reach maximal concentration or Tmax) - The plasma pharmacokinetics (time taken to reach maximal concentration or Tmax) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</outcome>
      <timepoint>Up to 148 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (Plasma terminal elimination half-life (t1/2?z) - The plasma pharmacokinetics (Plasma terminal elimination half-life (t1/2?z) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</outcome>
      <timepoint>Up to 148 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (Partial areas under the plasma concentration-time curve from zero time (predose) to selected times (t) after the subcutaneous administration (AUCt) - The plasma pharmacokinetics (Partial areas under the plasma concentration-time curve from zero time (predose) to selected times (t) after the subcutaneous administration (AUCt) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</outcome>
      <timepoint>Up to 148 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics after single and multiple doses of IONIS TMPRSS6-Lrx (Percentage of the administered dose excreted in urine (% Dose Excreted) - The plasma pharmacokinetics (Percentage of the administered dose excreted in urine (% Dose Excreted) of Ionis TMPRSS6-Lrx will be assessed following single and multiple dose SC administration</outcome>
      <timepoint>Up to 148 Days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must have given written informed consent and be able to comply with all study
             requirements

          -  Healthy males or females aged 18-65 inclusive at the time of Informed Consent

          -  Females must be non-pregnant and non-lactating, and either surgically sterile or post-
             menopausal

          -  Males must be surgically sterile, abstinent or using an acceptable contraceptive
             method

          -  BMI &lt; 32 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Clinically significant abnormalities in medical history or physical examination

          -  Clinically significant lab abnormalities that would render a subject unsuitable for
             inclusion

          -  Known history or positive test for HIV, HCV, or HBV

          -  Treatment with another Study Drug, biological agent, or device within one-month of
             Screening or 5 half-lives of investigational agent, whichever is longer

          -  Smoking &gt; 10 cigarettes per day

          -  Regular excessive use of alcohol within 6 months of screening

          -  Current use of concomitant medications other than occasional acetaminophen
             (paracetamol) or ibuprofen unless approved by Sponsor Medical Monitor

          -  Considered unsuitable for inclusion by the Investigator or Sponsor</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>6/06/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>44</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/03/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode>VIC 3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ionis Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose is to assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of
      IONIS TMPRSS6-Lrx Administered Subcutaneously to Healthy Volunteers</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03165864</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>